Winnow Wealth LLC Purchases New Holdings in United Therapeutics Corporation $UTHR

Winnow Wealth LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,972 shares of the biotechnology company’s stock, valued at approximately $962,000.

A number of other institutional investors and hedge funds have also bought and sold shares of UTHR. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter valued at about $31,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Down 0.9%

Shares of UTHR stock opened at $544.69 on Tuesday. The company has a 50 day moving average price of $568.47 and a 200-day moving average price of $519.64. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a market capitalization of $23.12 billion, a PE ratio of 20.11, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of analyst reports. Raymond James Financial initiated coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Finally, UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 624,043 shares of company stock worth $351,930,785 over the last three months. 8.60% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.